Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections
Open Access
- 1 October 2003
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 16 (4), 569-596
- https://doi.org/10.1128/cmr.16.4.569-596.2003
Abstract
SUMMARY: The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. Cidofovir (Vistide) has been officially approved for the treatment of CMV retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) has been approved for the treatment of HIV infections (i.e., AIDS), and adefovir dipivoxil (Hepsera) has been approved for the treatment of chronic hepatitis B. Nephrotoxicity is the dose-limiting side effect for cidofovir (Vistide) when used intravenously (5 mg/kg); no toxic side effects have been described for adefovir dipivoxil and tenofovir disoproxil fumarate, at the approved doses (Hepsera at 10 mg orally daily and Viread at 300 mg orally daily).Keywords
This publication has 232 references indexed in Scilit:
- Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancersOncogene, 2002
- Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 IsolatesAntimicrobial Agents and Chemotherapy, 2002
- Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and AdefovirClinical Pharmacokinetics, 1999
- CidofovirDrugs, 1999
- Adefovir DipivoxilDrugs, 1999
- Effect of Oral Probenecid Coadministration on the Chronic Toxicity and Pharmacokinetics of Intravenous Cidofovir in Cynomolgus MonkeysToxicological Sciences, 1998
- Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6Antiviral Research, 1995
- Kinetic Properties of Adenine Nucleotide Analogues Against Purified 5-Phosphoribosyl-1-pyrophosphate Synthetases fromE. coli, Rat Liver and Human ErythrocytesNucleosides and Nucleotides, 1995
- Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient miceEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993
- Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) DiseaseNew England Journal of Medicine, 1987